Article

Therapeutic Lifestyle Changes

Author and Disclosure Information

This month, Department Editor Scott Urquhart, PA-C, DFAAPA, turns the tables by

posing a question himself: Why don’t health care providers promote therapeutic lifestyle changes to their patients? Furthermore, he exhorts his colleagues to try harder in this area, even though he acknowledges the difficulty in getting buy-in from patients.


 

Q: Why aren’t we promoting therapeutic lifestyle changes (TLCs) as a “true” therapeutic option for our patients with type 2 diabetes?

From a clinician’s perspective, here are three actual cases:

1. A 47-year-old man presents to our endocrine practice with type 2 diabetes (T2DM) diagnosed three years ago by his primary care provider (PCP). He is being treated with metformin ER (500 mg bid), and glimepiride (4 mg/d), and his A1C is 8.2%. He has a BMI of 37 kg/m2, and since starting treatment for his diabetes he has not made any changes in his diet and does not exercise. His PCP informed him that he needs to start insulin right away since none of the remaining noninsulin options has the efficacy to lower his A1C to 6.5% (–1.7%).

2. A 53-year-old woman is referred to our endocrine practice with a new diagnosis of T2DM, made two weeks ago during a routine health maintenance exam. Since her A1C is 9.6%, her PCP told her she needed to start metformin plus insulin or a GLP-1 receptor agonist right away. Dietary note: The patient has drunk four to five (12-oz) cans of regular cola daily for the past two years and states, “I’ve never been an exerciser.”

3. A 44-year-old patient has a new diagnosis of T2DM and A1C of 7.4%. Patient was started on metformin (500 mg bid) before any TLCs were implemented.

In each case, the plan suggested by the PCP is an acceptable option based on current diabetes consensus algorithms. However, one problem I encounter time and time again is that TLCs have not been adequately discussed with the patients as a viable option. It is important to remember that patients with a recent diagnosis of T2DM who are drug naive will have the best glucose-lowering response to oral diabetes medications. Therefore, you will likely observe the highest A1C reductions compared with the average expected reductions in patients who are already taking other diabetes medications.

My experience has been that most PCPs—and even endocrinologists—will start metformin or other diabetes drugs as an initial medication and spend little time on promoting TLCs. I’m uncertain if it’s appointment time constraints, experience, or lack of belief that TLCs will actually be undertaken and continued by the patients. Patients often ask me why other health care providers didn’t enthusiastically promote changes in diet and exercise as a viable treatment option to improve glycemic control. It is not unusual to see patients decrease their A1C value by > 1.0%—and even experience hypoglycemia—on their current diabetes medications when carbohydrates and refined sugars are decreased and light-to-moderate exercise five to seven days per week is instituted.

Remember that the first-line therapy for hypertension, dyslipidemia, prediabetes, and T2DM is lifestyle modification. This first-line approach is all too often the last thing emphasized—or at least it receives little attention.

Q: Are we communicating to patients that TLCs actually have little value and we don’t think they have the ability to make necessary changes?

It seems to be the norm for many providers to evade this sometimes time-consuming yet underrated therapeutic discussion. It is as if we are convinced that the patients won’t make TLCs, so why spend the time discussing them? We essentially discount the patient’s willingness to change, and we default to the quick-and-easy “write a prescription,” since we have scientific studies that support the efficacy of current medications.

Instead, I say, we should be creating a sense of support, empowerment, credibility for change, and an opportunity for a victorious attitude in the patient, not one of failure. If you don’t spend valuable time discussing TLCs and the benefits they have on hypertension, dyslipidemia, and diabetes, then who will? I advise creating a referral list of those professionals who specialize in areas of TLCs, including certified diabetes educators, registered dieticians, behavioral health specialists, and certified personal trainers and fitness consultants.

T2DM is a progressive disease requiring additional medications over time, with the ultimate need for insulin. We should be cautious in how we use this information, as it may frustrate patients and make them feel, “Why should I try since it will not make any difference in the end?” The fact is that the progression of the disease can be altered with diet, exercise, and weight loss in such a fashion that some patients will be able to decrease their current diabetes medications and possibly even discontinue some, including insulin. Keep in mind that this will depend on the number of years they have had T2DM (ie, reflecting their insulin reserves).

Pages

Recommended Reading

Self-Monitoring of Glucose in Diabetes
Clinician Reviews
Choosing the Right Insulin
Clinician Reviews
New Standards of Care for Gestational Diabetes
Clinician Reviews
New Meeting to Help Primary Care Providers Tackle Diabetes, Endocrine Disorders
Clinician Reviews
Monitoring Thyroid Function
Clinician Reviews
Prolactinoma: A Case Study
Clinician Reviews
Hypercalcemia: Common Yet Challenging
Clinician Reviews
Thyroid Peroxidase Antibodies
Clinician Reviews
Early Identification of Pancreatic Cancer
Clinician Reviews
Insulin Pump Therapy for the Patient With Diabetes
Clinician Reviews